Kaleido CEO Dan Menichella (AP Photo/Andrew Harnik)
Flagship startup brings out the budget ax, chops staff and clinical plans as share price flounders
One of Flagship’s startups appears to be buckling under the pressure of a steadily falling stock price.
The microbiome company Kaleido Biosciences confirmed a new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
